|
시장보고서
상품코드
2039004
포도막염 치료 시장 : 치료법별, 질환 유형별, 유통 채널별, 지역별Uveitis Treatment Market, By Treatment Type, By Disease type, By Distribution Channel, By Geography |
||||||
포도막염 치료 시장은 2026년에 9억 600만 달러로 추정되며, 2033년까지 13억 8,900만 달러에 달할 것으로 전망됩니다. 2026년부터 2033년까지 CAGR 6.3%로 성장할 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 9억 600만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 6.30% | 2033년 시장 규모 예측: | 13억 8,900만 달러 |
포도막염은 눈의 포도막에 생기는 염증을 말합니다. 포도막은 홍채, 모양체, 맥락막의 세 가지 구성요소로 이루어진 눈의 중간층을 말합니다. 포도막염은 염증성 질환, 안구 손상, 바이러스, 박테리아, 곰팡이 등의 미생물 감염, 또는 강산이나 농약과 같은 특정 독성 화학제품에 노출되는 등 다양한 요인에 의해 발생합니다. 그러나 많은 경우, 이 질환의 원인은 아직 밝혀지지 않은 경우가 많습니다. 또한, 20세에서 50세 사이의 연령층에서 발병하는 것으로 알려져 있습니다. 이 질환은 포도막 내 염증 발생 부위에 따라 분류되며, 홍채에 염증을 일으키는 전방 포도막염을 포함한 세 가지 유형으로 분류됩니다. 전방 포도막염은 가장 흔한 유형입니다.
시장 역학
시장 진입 기업들의 신제품 출시 증가는 예측 기간 동안 세계 포도막염 치료제 시장을 견인할 것으로 예상됩니다. 예를 들어, 2022년 2월 7일, 조지아에 본사를 두고 처방용 안과 의약품의 상업화 및 개발을 전문으로 하는 바이오제약 기업 알리메라 사이언스(Alimera Sciences)는 스페인에서 포도막염 치료제 'ILUVIEN(플루오시놀론 아세토나이드 유리체내 임플란트)'의 출시를 발표했습니다. 체내 임플란트)'의 발매를 발표했습니다. 일루비엔은 현재 치료법으로 충분한 효과를 얻지 못하는 만성 당뇨병성 황반부종(DME)으로 인한 시력저하를 치료하고 안구 후방을 침범하는 재발성 비감염성 포도막염(NIPU)의 재발을 예방하기 위해 유럽에서 사용이 승인된 서방형 유리체강내 임플란트입니다. 일루비엔은 코르티코스테로이드인 플루오시놀론 아세토나이드를 36개월 동안 서브마이크로그램 단위로 방출하도록 설계되어, 환자는 치료 간격이 길어질수록 시력을 더 오래 유지할 수 있습니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 수익 창출 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 저해요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서에서는 다음과 같은 매개변수(회사 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략)를 기반으로 세계 포도막염 치료제 시장의 주요 기업 프로파일을 소개합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 세계 포도막염 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 포도막염 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 포도막염 치료 시장 : 치료법별, 2021-2033년
제5장 세계의 포도막염 치료 시장 : 질환 유형별, 2021-2033년
제6장 세계의 포도막염 치료 시장 : 유통 채널별, 2021-2033년
제7장 세계의 포도막염 치료 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSM 26.06.04Uveitis Treatment Market is estimated to be valued at USD 906 Mn in 2026 and is expected to reach USD 1,389 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 906 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.30% | 2033 Value Projection: | USD 1,389 Mn |
Uveitis refers to inflammation caused in the uvea of the eye. A uvea is the middle layer of the eye that consists of three components namely iris, cilliary body, and the choroid. Uveitis is caused by various factors such as inflammatory diseases, injuries in the eye, microbial infections such as viral, bacterial, and fungal infection or exposure to certain toxic chemicals such as strong acids or pesticides. However, in many cases the cause of this condition remains unknown. It is also found to be effecting people belonging to the age group of 20-50 years. The condition is classified based on the location of inflammation in the uvea and is categorized in three types including anterior uveitis that causes inflammation in the iris and is the most commonly encountered type.
Market Dynamics
Increasing product launches by market players is expected to drive the global uveitis treatment market over the forecast period. For instance, in February 7, 2022, Alimera Sciences which is a biopharmaceutical company based in Georgia that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced that it has announced Launch of ILUVIEN (fluocinolone acetonide intravitreal implant) for Uveitis in Spain. ILUVIEN is a sustained release intravitreal implant approved for use in Europe to treat vision loss brought on by chronic diabetic macular edema (DME), which is thought to be under responsive to current treatments, as well as to prevent relapse in cases of recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU). ILUVIEN is made to deliver sub-microgram quantities of the corticosteroid fluocinolone acetonide for 36 months, which helps patients preserve their vision for longer between treatments.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global uveitis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AbbVie, Novartis AG, Bausch Health Companies Inc., Galapagos NV, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Tarsier Pharma Ltd, Santen Pharmaceutical Co., Ltd., Bausch & Lomb Incorporated, Sanofi and Regeneron Pharmaceuticals, Inc., Alimera Sciences
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global uveitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global uveitis treatment market
Market Segmentation
- By Treatment Type Insights (Revenue, USD Mn, 2021 - 2033)
- Corticosteroids
- Immunosuppressant
- Monoclonal Antibodies
- Cycloplegic Agents
- Antibiotics
- Antivirals
- Antifungal
- Analgesics
- By Disease Type Insights (Revenue, USD Mn, 2021 - 2033)
- Anterior Uveitis
- Posterior Uveitis
- Intermediate Uveitis
- Pan uveitis
- By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- By Region Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players in the Uveitis Treatment Market
- AbbVie
- Novartis AG
- Bausch Health Companies Inc.
- Galapagos NV
- EyePoint Pharmaceuticals, Inc.
- Clearside Biomedical
- Tarsier Pharma Ltd
- Santen Pharmaceutical Co., Ltd.
- Bausch & Lomb Incorporated
- Sanofi
- Regeneron Pharmaceuticals
- Alimera Sciences
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pipeline Analysis
- PEST Analysis
4. Global Uveitis Treatment Market, By Treatment Type, 2021 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Immunosuppressant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Monoclonal Antibodies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Cycloplegic Agents
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Antivirals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Antifungal
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Analgesics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Uveitis Treatment Market, By Disease Type, 2021 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Anterior Uveitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Posterior Uveitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Intermediate Uveitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Pan uveitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Uveitis Treatment Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Drug Stores
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Uveitis Treatment Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- AbbVie
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bausch Health Companies Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Galapagos NV
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- EyePoint Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Clearside Biomedical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Tarsier Pharma Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Santen Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bausch & Lomb Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alimera Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
